Anti-Fibrinolytic Drugs - Iran

  • Iran
  • The Anti-Fibrinolytic Drugs market in Iran is expected to witness significant growth in the coming years.
  • According to projections, the revenue in this market is estimated to reach US$126.70m by 2024.
  • Furthermore, it is anticipated that the market will experience a steady annual growth rate of 3.98% from 2024 to 2029.
  • This growth trajectory would result in a market volume of US$154.00m by 2029.
  • When compared to other countries, United States is poised to generate the highest revenue in the Anti-Fibrinolytic Drugs market.
  • In 2024, it is estimated that the revenue United States will reach a staggering US$9,858.00m.
  • This demonstrates the dominance of the US market in this market.
  • Iran is experiencing a growing demand for anti-fibrinolytic drugs due to an increasing prevalence of cardiovascular diseases in the country.

Key regions: United Kingdom, Brazil, Europe, France, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Anti-Fibrinolytic Drugs are used to prevent the breakdown of blood clots in the body. In Iran, the market for these drugs has been developing steadily over the past few years.

Customer preferences:
There is a growing demand for Anti-Fibrinolytic Drugs in Iran due to an increase in the number of surgeries being performed. Patients who undergo surgery are at risk of excessive bleeding, and these drugs help to prevent this from happening. Additionally, there is a growing awareness among the population about the benefits of these drugs, which has led to an increase in demand.

Trends in the market:
One of the major trends in the Anti-Fibrinolytic Drugs market in Iran is the shift towards more advanced and effective drugs. There is a growing preference for drugs that are more targeted and have fewer side effects. This trend is being driven by advancements in medical research and technology, as well as increasing competition in the market.Another trend in the market is the increasing use of generic drugs. This is due to the lower cost of these drugs, which makes them more accessible to a wider range of patients. Additionally, there is a growing trend towards self-medication, which has led to an increase in demand for over-the-counter Anti-Fibrinolytic Drugs.

Local special circumstances:
One of the unique aspects of the Anti-Fibrinolytic Drugs market in Iran is the role of the government. The Iranian government heavily regulates the pharmaceutical industry, which has led to a more stable market. Additionally, the government has implemented policies to encourage the production of generic drugs, which has helped to increase access to these drugs.

Underlying macroeconomic factors:
The Iranian economy has been facing significant challenges in recent years, including sanctions and inflation. However, the pharmaceutical industry has remained relatively stable due to government support and a growing demand for healthcare services. As the population continues to age and healthcare needs increase, the demand for Anti-Fibrinolytic Drugs is expected to continue to grow.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)